The inhibitory effect of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, compared with enoxaparin and r-hirudin on ex vivo thrombin generation in human plasma

Thrombosis Research

Volumn 113, Issue 1, 2004, Pages 85-91

  Boström, Stig L ^a   Hansson, Göran F H ^a   Sarich, Troy C ^b   Wolzt, Michael ^c  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Direct thrombin inhibitor; DTI; Endogenous thrombin potential; Enoxaparin; ETP; F; Factor; Hirudin; Intravenous; Iv; LMWH; Low molecular weight heparin; Melagatran; Platelet poor plasma; PPP; Sc; Thrombin generation; Ximelagatran

Indexed keywords

ENOXAPARIN; LEPIRUDIN; MELAGATRAN; PLACEBO; RECOMBINANT HIRUDIN; TAP WATER; THROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN; XIMELAGATRAN;

ADULT; ARTICLE; ASSAY; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; EX VIVO STUDY; HUMAN; HUMAN EXPERIMENT; LATENT PERIOD; MALE; MEASUREMENT; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; RANDOMIZATION; THROMBIN TIME; THROMBOCYTE; VENOUS BLOOD; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; AREA UNDER CURVE; AZETIDINES; BENZYLAMINES; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENOXAPARIN; HIRUDINS; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; PRODRUGS; SAFETY; THROMBIN; TIME FACTORS;

EID: 1842737656     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.02.009     Document Type: Article

References (28)

1. Walenga J.M., Fareed J. Current status on new anticoagulant and antithrombotic drugs and devices. Curr. Opin. Pulm. Med. 3:1997;291-302.
2. Hirsh J., Warkentin T.E., Shaughnessy S.G., Anand S.S., Halperin J.L., Raschke R.et al. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 119:2001;64S-94S.
3. Greinacher A., Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation. 103:2001;1479-1484.
4. Scatena R. Bivalirudin: a new generation antithrombotic drug. Expert Opin. Investig. Drugs. 9:2000;1119-1127.
5. McKeage K., Plosker G.L. Argatroban. Drugs. 61:2001;515-522.
6. Gustafsson D., Nystrom J., Carlsson S., Bredberg U., Eriksson U., Gyzander E.et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 101:2001;171-181.
7. Gustafsson D., Antonsson T., Bylund R., Eriksson U., Gyzander E., Nilsson I.et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemost. 79:1998;110-118.
8. Eriksson B.I.et al. on behalf of the EXPRESS Study Group The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J. Thromb. Haemost. 1:2003;1490-1496.
9. Francis C.W.et al. for the EXULT A Study Group Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N. Engl. J. Med. 349:2003;1703-1712.
10. Eriksson H., Wåhlander K., Gustafsson D., Welin L.T., Frison L., Schulman S. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J. Thromb. Haemost. 1:2003;41-47.
11. Huisman M.V. on behalf of the THRIVE Treatment Study Investigators Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study. J. Thromb. Haemost. 1(Suppl. 1):2003;OC003.
12. Schulman S.et al. THRIVE III Investigators Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N. Engl. J. Med. 349:2003;1713-1721.
13. Petersen P.et al. for the SPORTIF II Investigators Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J. Am. Coll. Cardiol. 41:2003;1445-1451.
14. The Executive Steering Committee on behalf of the SPORTIF III Investigators Stroke prevention using the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation: the SPORTIF III trial. Lancet. 362:2003;1691-1698.
15. Wallentin L., Wilcox R., Weaver W.D.et al. Efficacy and safety of long term treatment with the oral direct thrombin inhibitor ximelagatran, in combination with acetylsalicylic acid, in patients with a recent acute myocardial infarction: the ESTEEM trial. Lancet. 362:2003;789-797.
16. Boström S.L., Dagnelid E., Hansson G.F.H., Ulvinge J.-C. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran. Blood Coagul. Fibrinolysis. 15:2004;15-30.
17. Boström S.L., Hansson G.F.H., Kjaer M., Sarich T.C. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin, on the endogenous thrombin potential in venous blood from healthy male volunteers. Blood Coagul. Fibrinolysis. 14:2003;457-462.
18. Prasa D., Svendsen L., Sturzebecher J. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb. Haemost. 77:1997;498-503.
19. Hemker H.C., Willems G.M., Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb. Haemost. 56:1986;9-17.
20. Hemker H.C., Wielders S., Kessels H., Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb. Haemost. 70:1993;617-624.
21. Sarich T.C., Wolzt M., Eriksson U.G., Mattsson C., Schmidt A., Elg S.et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J. Am. Coll. Cardiol. 41:2003;557-564.
22. Hansson G. Method for determining free thrombin concentration. International patent PCT/SE2003/01273; 2003.
23. Lindhout T., Blezer R., Hemker H.C. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb. Haemost. 64:1990;464-468.
24. Eichinger S., Wolzt M., Schneider B., Nieszpaur-Los M., Heinrichs H., Lechner K.et al. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin). Arterioscler. Thromb. Vasc. Biol. 15:1995;886-892.
25. Wolzt M., Eder M., Weltermann A., Entlicher J., Eichler H.-G., Kyrle P.A. Comparison of the effects of different low molecular weight heparins on the hemostatic system activation in vivo in man. Thromb. Haemost. 78:1997;876-879.
26. Braun P.J., Dennis S., Hofsteenge J., Stone S.R. Use of site-directed mutagenesis to investigate the basis for the specificity of hirudin. Biochemistry. 27:1988;6517-6522.
27. Beguin S., Welzel D., Al Dieri R., Hemker H.C. Conjectures and refutations on the mode of action of heparins. The limited importance of anti-factor Xa activity as a pharmaceutical mechanism and a yardstick for therapy. Haemostasis. 29:1999;170-178.
28. Sandset P.M., Bendz B., Hansen J.B. Physiological function of tissue factor pathway inhibitor and interaction with heparins. Haemostasis. 30(Suppl. 2):2000;48-56.